News & Updates

Esketamine combined with a serotonin-norepinephrine reuptake inhibitor (SNRI) reduces rates of mortality, hospitalizations, and depressive relapses, while esketamine combined with a selective serotonin reuptake inhibitor (SSRI) decreases the incidence of suicidal attempts, a real-world comparative effectiveness study on treatment-resistant depression (TRD) has shown.

Eleven oral bacterial species may serve as biomarkers for early detection of autism through simple oral sampling, with an accuracy of 81 percent, according to a cross-disciplinary research team from the Faculty of Dentistry and the Department of Psychology of the University of Hong Kong (HKU).

Repeated microdosing of lysergic acid diethylamide (LSD) is not more efficacious than placebo in reducing attention-deficit/hyperactivity disorder (ADHD) symptoms in adults, a randomized controlled trial (RCT) has shown.

Combination treatment with esketamine plus either a selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI) is beneficial in treatment-resistant depression (TRD), with notable variations in outcomes depending on the choice of antidepressant class, as shown in a large retrospective study.